The dental management of patients with spontaneous acquired factor VIII inhibitors. 1986

D M Hasson, and A E Poole, and B de la Fuente, and L W Hoyer

The histories of two patients without hemophilia but with spontaneous acquired factor VIII inhibitors are reported. A protocol is suggested for the combined hematologic and dental management of such patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001778 Blood Coagulation Disorders Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions. Coagulation Disorders, Blood,Disorders, Blood Coagulation,Blood Coagulation Disorder,Coagulation Disorder, Blood,Disorder, Blood Coagulation
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003730 Dental Care for Disabled Dental care for the emotionally, mentally, or physically disabled patient. It does not include dental care for the chronically ill ( Dental Care for Handicapped,Dentistry for Disabled,Dentistry for Handicapped,Disabled, Dentistry for,Handicapped, Dentistry for
D003894 Deamino Arginine Vasopressin A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR. Desmopressin,Vasopressin, Deamino Arginine,1-Deamino-8-D-arginine Vasopressin,1-Desamino-8-arginine Vasopressin,Adiuretin,Adiuretin SD,Apo-Desmopressin,DDAVP,Desmogalen,Desmopressin Acetate,Desmopressin Monoacetate,Desmopressin Monoacetate, Trihydrate,Desmopressine Ferring,Desmospray,Desmotabs,Minirin,Minurin,Nocutil,Octim,Octostim,Acetate, Desmopressin,Arginine Vasopressin, Deamino,Ferring, Desmopressine,Monoacetate, Desmopressin,Monoacetate, Trihydrate Desmopressin,Trihydrate Desmopressin Monoacetate,Vasopressin, 1-Deamino-8-D-arginine,Vasopressin, 1-Desamino-8-arginine
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015119 Aminocaproic Acid An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. 6-Aminocaproic Acid,6-Aminohexanoic Acid,epsilon-Aminocaproic Acid,Amicar,CY-116,Capralense,Capramol,Caproamin,Caprocid,Caprolest,Epsamon,Epsikapron,Hemocaprol,Hexalense,6 Aminocaproic Acid,6 Aminohexanoic Acid,CY 116,CY116,epsilon Aminocaproic Acid

Related Publications

D M Hasson, and A E Poole, and B de la Fuente, and L W Hoyer
September 2008, Current opinion in hematology,
D M Hasson, and A E Poole, and B de la Fuente, and L W Hoyer
April 1994, Seminars in hematology,
D M Hasson, and A E Poole, and B de la Fuente, and L W Hoyer
October 2021, Cureus,
D M Hasson, and A E Poole, and B de la Fuente, and L W Hoyer
August 1987, Transfusion medicine reviews,
D M Hasson, and A E Poole, and B de la Fuente, and L W Hoyer
July 2008, Blood,
D M Hasson, and A E Poole, and B de la Fuente, and L W Hoyer
January 2002, Haemophilia : the official journal of the World Federation of Hemophilia,
D M Hasson, and A E Poole, and B de la Fuente, and L W Hoyer
February 1997, Annals of hematology,
D M Hasson, and A E Poole, and B de la Fuente, and L W Hoyer
February 1988, Lancet (London, England),
D M Hasson, and A E Poole, and B de la Fuente, and L W Hoyer
October 2006, American journal of hematology,
D M Hasson, and A E Poole, and B de la Fuente, and L W Hoyer
October 1997, American journal of hematology,
Copied contents to your clipboard!